Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated:  3/2/2016
The Pharmacy; Inc.
mi
from
Bennington, VT
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease
Status: Enrolling
Updated: 3/2/2016
The Pharmacy; Inc.
mi
from
Bennington, VT
Click here to add this to my saved trials
Alzheimer's Disease Multiple Intervention Trial
Alzheimer's Disease Multiple Intervention Trial
Status: Enrolling
Updated:  3/7/2016
Wishard Health Services
mi
from
Indianapolis, IN
Alzheimer's Disease Multiple Intervention Trial
Alzheimer's Disease Multiple Intervention Trial
Status: Enrolling
Updated: 3/7/2016
Wishard Health Services
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Bridging Study of C11 PiB and F18 Flutemetamol Brain PET
Bridging Study of C11 PiB and F18 Flutemetamol Brain PET
Status: Enrolling
Updated:  3/9/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Bridging Study of C11 PiB and F18 Flutemetamol Brain PET
Bridging Study of C11 PiB and F18 Flutemetamol Brain PET
Status: Enrolling
Updated: 3/9/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated:  3/29/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated: 3/29/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated:  3/29/2016
Rush University Medical Center
mi
from
Chicago, IL
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated: 3/29/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated:  3/29/2016
Alexian Brothers Neurosciences Institute
mi
from
Elk Grove Village, IL
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated: 3/29/2016
Alexian Brothers Neurosciences Institute
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated:  3/29/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated: 3/29/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated:  3/29/2016
Alzheimer's Disease Center, Quincy Medical Center
mi
from
Quincy, MA
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated: 3/29/2016
Alzheimer's Disease Center, Quincy Medical Center
mi
from
Quincy, MA
Click here to add this to my saved trials
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated:  3/29/2016
Neurological Associates of Albany, PC
mi
from
Albany, NY
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated: 3/29/2016
Neurological Associates of Albany, PC
mi
from
Albany, NY
Click here to add this to my saved trials
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated:  3/29/2016
Indiana Medical Research
mi
from
Indianapolis, IN
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Status: Enrolling
Updated: 3/29/2016
Indiana Medical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
Miami Jewish Health Systems
mi
from
Miami, FL
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
Miami Jewish Health Systems
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
Roskamp Institute Clinic
mi
from
Sarasota, FL
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
Roskamp Institute Clinic
mi
from
Sarasota, FL
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
Palm Beach Neurology and Premiere Research Institute
mi
from
West Palm Beach, FL
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
Palm Beach Neurology and Premiere Research Institute
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
Cleveland Clinic Lou Ruvo Brain Center
mi
from
Las Vegas, NV
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
Cleveland Clinic Lou Ruvo Brain Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
Cleveland Clinic Center for Brain Health Lakewood Hospital
mi
from
Cleveland, OH
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
Cleveland Clinic Center for Brain Health Lakewood Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
NYU Langone Medical Center
mi
from
New York, NY
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated:  3/29/2016
Assaf Harofe Medical Center
mi
from
Beer Yaakov,
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients
Status: Enrolling
Updated: 3/29/2016
Assaf Harofe Medical Center
mi
from
Beer Yaakov,
Click here to add this to my saved trials
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated:  4/11/2016
Methodist Center for Geriatric Medicine
mi
from
Indianapolis, IN
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated: 4/11/2016
Methodist Center for Geriatric Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated:  4/11/2016
St. Vincent Center for Healthy Aging
mi
from
Indianapolis, IN
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated: 4/11/2016
St. Vincent Center for Healthy Aging
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated:  4/11/2016
Touchpoint
mi
from
Fishers, IN
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated: 4/11/2016
Touchpoint
mi
from
Fishers, IN
Click here to add this to my saved trials
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated:  4/11/2016
University Clinical Neurology
mi
from
Indianapolis, IN
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated: 4/11/2016
University Clinical Neurology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated:  4/11/2016
Wishard Health Services
mi
from
Indianapolis, IN
Comparative Research of Alzheimer's Disease Drugs
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs
Status: Enrolling
Updated: 4/11/2016
Wishard Health Services
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Tucson, AZ
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Costa Mesa, CA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Encino, CA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Glendale, CA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Long Beach, CA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Redding, CA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Redding, CA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
San Diego, CA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Atlantis, FL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Atlantis, FL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Brooksville, FL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Brooksville, FL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Delray Beach, FL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Fort Myers, FL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Lake Worth, FL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Lake Worth, FL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Miami, FL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Orlando, FL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
St. Petersburg, FL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Weston, FL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Weston, FL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Columbus, GA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Columbus, GA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Douglasville, GA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Douglasville, GA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Chicago, IL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Park Ridge, IL
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Bangor, ME
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Bangor, ME
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Chestnut Hill, MA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Chestnut Hill, MA
Click here to add this to my saved trials
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Plymouth, MA
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Plymouth, MA
Click here to add this to my saved trials